32. 从 2020 年 11 月开始，世界一些地区的各种制药公司和公共医疗机构开始宣布其 COVID-19 候选疫苗具有惊人的有效性和安全性。令人遗憾的是，这些声明只是加剧了已然不公的状况，加速了疫苗竞赛。甚至在这些声明之前，已经有抱怨称，“仅占世界人口 13%的富裕国家已经垄断了 COVID-19 主要候选疫苗所承诺剂数的一半以上(51%)”。99 此外，乐施会长期以来一直警告说，主要制药公司根本没有能力生产足够所有人使用的疫苗，因此，至少在 2022 年之前，世界有近三分之二(61%)的人口无法获得疫苗。100 即便 2020 年 12 月开始实际疫苗接种之时，情况也没有显著改善。更加令人担忧的是，有报告称，一些国家可能要到 2024 年才能获得数量可观的疫苗。101
32. From November 2020, various drug companies and public medical institutes in certain parts of the world began announcing the impressive effectiveness and safety levels of their COVID-19 vaccine candidates. Unfortunately, those announcements only accelerated an already inequitable situation and the race for vaccines. Even before the announcements, complaints were made that “wealthy nations representing just 13 per cent of the world’s population have already cornered more than half (51 per cent) of the promised doses of leading COVID-19 vaccine candidates”.99 In addition, Oxfam has long warned that the major pharmaceutical companies simply do not have the capacity to make enough vaccines for everyone, leaving nearly two thirds (61 per cent) of the world’s population without the prospect of receiving a vaccine until at least 2022.100 Even at the commencement of the roll out of actual vaccinations, in December 2020, the situation had not improved significantly. That is even more worrisome against the backdrop of reports that some countries may not acquire a significant quantity of vaccines until 2024.101